Dalton Pharma Services has signed a drug-development and manufacturing contract with Ramsey Lake Pharmaceutical Corp. (RLPC) to support toxicology studies for VR23, the company’s β2-targeting proteasome inhibitor in development to treat cancer. The agreement includes the synthesis of VR23 by Dalton as well as the development of analytical testing methods and execution of a stability study.

Ramsey Lake Pharma is a privately held company developing proteasome inhibitors as cancer care treatments. Its lead candidate, VR23, a small-molecule cancer therapeutic, shows potential as a proteasome inhibitor, inhibiting tumor growth as a single agent. When used in combination with gold-standard anticancer drugs, VR23 can increase efficacy while reducing toxicity, according to information from Dalton.

Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a cGMP contract service provider of chemistry, drug development and dosage form manufacturing services with expertise in medicinal chemistry, process development and reaction optimization, as well as formulation development, analytical testing and development, and cGMP manufacturing, including cGMP active pharmaceutical ingredient production and cGMP sterile filling services.

Source: Dalton Pharma Services